RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective RORγt inverse agonist, with improved drug-like properties, with an IC50 of 63.8 nM.In Vitro: RORγt inverse agonist 13 (Compound 3i) exhibits activity with an inhibition of 76% at 0.3?μM in Th17 cell differentiation assay.In Vivo: RORγt inverse agonist 13 (Compound 3i, 25 mg/kg, Orally, twice daily) demonstrats excellent in vivo PK profile in mice and good in vivo efficacy in an IMQ-induced psoriasis mice model.